Melt doses first subject in Phase III trial of non-opioid sedation tablet

Melt doses first subject in Phase III trial of non-opioid sedation tablet

Submitted by admin on June 7, 2024 - 11:11am
Source: 
Clinical Trials Arena
News Tags: 
Melt Pharmaceuticals
clinical trials
MELT-300
cataract surgery
Headline: 
Melt doses first subject in Phase III trial of non-opioid sedation tablet
snippet: 

Melt Pharmaceuticals has dosed the first subject in its Phase III clinical trial of MELT-300 being developed as a needle and opioid-free sedation option for patients undergoing cataract surgery.

Do Not Allow Advertisers to Use My Personal information